Tetra Bio-Pharma Inc. (TBP.TO)
| Previous Close | 0.0550 |
| Open | 0.0600 |
| Bid | 0.0550 x N/A |
| Ask | 0.0600 x N/A |
| Day's Range | 0.0550 - 0.0600 |
| 52 Week Range | 0.0500 - 0.3400 |
| Volume | |
| Avg. Volume | 286,198 |
| Market Cap | 23.263M |
| Beta (5Y Monthly) | 1.99 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1100 |
| Earnings Date | Apr 13, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Baystreet
Stocks in play: Tetra Bio-Pharma Inc
Announces the launch of its new wholly owned subsidiary 'Tetra Bio-Pharma Australia Pty Ltd', an Australian-based ...
- CNW Group
Tetra Bio-Pharma Opens New Subsidiary in Australia and Provides Regulatory Update
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announces the launch of its new wholly owned subsidiary 'Tetra Bio-Pharma Australia Pty Ltd' ("TBP-AU"), an Australian-based research company focused on the execution of clinical trials in Australia. This represents Tetra's second foreign subsidiary and is in line with the Company's global expansion strategy for QIXLEEF™, and other future drug can
- CNW Group
Tetra Bio-Pharma Announces Voting Results of 2022 Annual General and Special Meeting
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, held its annual general and special meeting (the "Meeting") of its holders of common shares (the "Shareholders") virtually on May 30, 2022. The Company is pleased to announce that all matters presented for approval at the Meeting were approved, except with respect to the proposed share consolidation of the issued and outstanding common shares of
